There are 412 resources available
1363P - Genomic heterogeneity of ALK rearrangements and acquired resistance pathways in ALK+ Advanced non-small cell lung cancer (NSCLC) treated with upfront alectinib: Preliminary results of GALILEO project
Presenter: Emanuele Vita
Session: Poster session 19
1444P - Sintilimab with two cycles nab-paclitaxel / platinum as first line therapy for advanced squamous non-small-cell lung cancer: The final analysis and biomarker results
Presenter: Huijuan Wang
Session: Poster session 20
1244P - AI-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners
Presenter: Ramona Erber
Session: Poster session 14
1340P - Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study
Presenter: Dongming Zhang
Session: Poster session 19
1312MO - Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)
Presenter: Enric Carcereny
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1356P - 10-year survivors treated with tyrosine kinase inhibitor for advanced non-small cell lung cancer
Presenter: Yu Tanaka
Session: Poster session 19
LBA62 - Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study
Presenter: Andrea Riccardo Filippi
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1381P - TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION
Presenter: Petros Christopoulos
Session: Poster session 20
1276P - Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD
Presenter: Kiyotaka Yoh
Session: Poster session 04
1282P - Concordance of PD-L1 expression between biopsy and matched surgical specimen in early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD
Presenter: Yoshitaka Zenke
Session: Poster session 04